-
By Norman R. Relkin, MD, PhD
Associate Professor of Clinical Neurology and Neuroscience at New York Presbyterian Hospital-Cornell Campus.
Dr. Relkin is on the speaker's bureau of Pfizer, Eisai, and Athena Diagnostics and does research for Pfizer and Merck.
-
White-Coat HTN
Make Diabetics Walk
Treatment of Complicated Grief
-
-
By Ralph R. Hall, MD, FACP
Emeritus Professor of Medicine, University of Missouri, Kansas City School of Medicine
Disclosure; Dr. Hall is a consultant for Sanofi-Aventis.
Synopsis: Exercise and stress management improved markers of cardiovascular disease more than usual care alone.
-
By Joseph E. Scherger, MD, MPH
Clinical Professor, University of California, San Diego
Disclosure; Dr. Scherger reports no financial conflicts to this field of study.
-
By Harold L. Karpman, MD
Clinical Professor of Medicine, UCLA School of Medicine
Disclosure; Dr. Karpman reports no financial conflicts of interest in this field of study.
Despite the recent explosion of pharmacologic agents available for the treatment of congestive heart failure (CHF), many patients continue to be severely symptomatic and their prognosis remains poor.
-
By Malcolm Robinson, MD, FACP, FACG
Emeritus Clinical Professor of Medicine, University of Oklahoma College of Medicine, Oklahoma City, OK
Disclosure; Dr. Robinson serves as a consultant for TAP, Pfizer, Janssen, Eisai, J&J-Merck, and Procter & Gamble, is on the speakers bureau of Janssen, Eli Lilly, Solvay, TAP, and Aventis, and does research for Forest Labs, Wyeth-Ayerst, AstraZeneca,and Centocor.
Synopsis: Rifaximin, a newly released nonabsorbed antibiotic, appears to safely and effectively prevent the onset and substantial morbidity of travelers diarrhea.
-
By William T. Elliott, MD, FACP, and James Chan, PharmD, PhD
Dr. Elliott is Chair, Formulary Committee, Northern California Kaiser Permanente; Asst. Clinical Professor of Medicine, University of California, San Francisco; Dr. Chan is Pharmacy Quality and Outcomes Manager, Kaiser Permanente, Oakland, CA
Drs. Chan and Elliott report no financial relationships to this field of study.
-
-
Roche is Under Pressure Over Its Antiviral Drug Tamiflu; ACE Inhibitors or ARBs for Prediabetics?; Xigris is Approved for Severe Sepsis; ACE Inhibitors Inhibiting Aortic Valve Stenosis?; FDA Actions
